DGAP-News: ViGeneron GmbH / Key word(s): Agreement 
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy 
2021-01-18 / 08:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy 
The companies will evaluate ViGeneron's proprietary, intravitreally injected vgAAV vectors for delivering a novel 
therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease 
Munich, Germany, January 18, 2021 - ViGeneron GmbH, a gene therapy company, today announced a research collaboration to 
utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited ("Daiichi 
Sankyo"), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic 
disease. ViGeneron's vgAAVs enable the efficient transduction of target cells via intravitreal injection that allows 
efficient lateral spreading and minimizes the risk of collateral damage caused by conventional subretinal injection. 
"There is significant unmet medical need for a sustained therapy to treat eye diseases. ViGeneron's innovative gene 
therapy expertise combined with Daiichi Sankyo's ophthalmic knowledge creates the potential to develop a sustained 
novel gene therapy to overcome the current limitations in treating this highly prevalent ophthalmic disease," commented 
Dr. Caroline Man Xu, Co-founder and CEO of ViGeneron. "We look forward to working with Daiichi Sankyo to drive 
cutting-edge innovative science and to create an effective treatment for patients." 
Under the agreement, Daiichi Sankyo and ViGeneron will jointly conduct the first stage research and Daiichi Sankyo will 
have the option to negotiate a follow-on collaboration agreement for an undisclosed therapeutic target in the highly 
prevalent eye disease. Financial terms of the collaboration are not disclosed. 
About ViGeneron 
ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical 
need, as well as partnering with leading biopharmaceutical players in other disease areas. The company's pipeline is 
built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vector 
platform, allows superior transduction efficiency and intravitreal, a less invasive treatment administration. The 
second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was 
founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene 
therapy programs and is located in Munich, Germany. For further information, please visit www.vigeneron.com. 
ViGeneron Contact   ViGeneron Media and Investor Contact 
ViGeneron GmbH      MC Services AG 
Dr. Caroline Man Xu Julia von Hummel / Shaun Brown 
Co-Founder and CEO  phone: +49 (0)89 2102280 
info@vigeneron.com  vigeneron@mc-services.eu -----------------------------------------------------------------------------------------------------------------------

2021-01-18 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

1161007 2021-01-18

(END) Dow Jones Newswires

January 18, 2021 02:01 ET (07:01 GMT)